<li>acarbose<p>acarbose, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>albiglutide<p>albiglutide, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>alogliptin<p>alogliptin, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>aripiprazole<p>aripiprazole, insulin glargine. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>asenapine<p>asenapine, insulin glargine. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>aspirin<p>aspirin increases effects of insulin glargine by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required.</p></li><li>atazanavir<p>atazanavir decreases effects of insulin glargine by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>benazepril<p>benazepril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Enhanced hypoglycemic effects; Monitor blood glucose.</p></li><li>bezafibrate<p>bezafibrate increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.</p></li><li>bitter melon<p>bitter melon increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>canagliflozin<p>insulin glargine, canagliflozin.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.<span><br><br></span>canagliflozin, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>captopril<p>captopril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor.  Both drugs decrease blood glucose. Monitor blood glucose.</p></li><li>chlorpropamide<p>chlorpropamide, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>cinnamon<p>cinnamon increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Potential for hypoglycemia.</p></li><li>ciprofibrate<p>ciprofibrate increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.</p></li><li>clozapine<p>clozapine, insulin glargine. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>dapagliflozin<p>insulin glargine, dapagliflozin.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with dapagliflozin.<span><br><br></span>dapagliflozin, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>darunavir<p>darunavir decreases effects of insulin glargine by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>deflazacort<p>insulin glargine and deflazacort both decrease  serum potassium. Use Caution/Monitor.</p></li><li>dexfenfluramine<p>dexfenfluramine increases effects of insulin glargine by Other (see comment). Use Caution/Monitor. 
Comment: Dexfenfluramine enhances glucose uptake in peripheral tissue, increasing risk of hypoglycemia.</p></li><li>dichlorphenamide<p>dichlorphenamide and insulin glargine both decrease  serum potassium. Use Caution/Monitor.</p></li><li>dulaglutide<p>dulaglutide, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>empagliflozin<p>empagliflozin, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with SGLT2 inhibitors.</p></li><li>enalapril<p>enalapril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>ethinylestradiol<p>ethinylestradiol decreases effects of insulin glargine by pharmacodynamic antagonism. Use Caution/Monitor. Oral contraceptives may decrease hypoglycemic effects of antidiabetics by impairing glucose tolerance. Monitor for glycemic control in diabetic patients.</p></li><li>exenatide injectable solution<p>exenatide injectable solution, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>exenatide injectable suspension<p>exenatide injectable suspension, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>fenfluramine<p>fenfluramine increases effects of insulin glargine by Other (see comment). Use Caution/Monitor. 
Comment: Fenfluramine enhances glucose uptake in peripheral tissue, increasing risk of hypoglycemia.</p></li><li>fenofibrate<p>fenofibrate increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.</p></li><li>fenofibrate micronized<p>fenofibrate micronized increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.</p></li><li>fenofibric acid<p>fenofibric acid increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.</p></li><li>fleroxacin<p>fleroxacin increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>fosamprenavir<p>fosamprenavir decreases effects of insulin glargine by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>fosinopril<p>fosinopril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>gemfibrozil<p>gemfibrozil increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.</p></li><li>gemifloxacin<p>gemifloxacin increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>glimepiride<p>glimepiride, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>glipizide<p>glipizide, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>glyburide<p>glyburide, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>iloperidone<p>iloperidone, insulin glargine. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>imidapril<p>imidapril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>indinavir<p>indinavir decreases effects of insulin glargine by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>isocarboxazid<p>isocarboxazid increases effects of insulin glargine by unknown mechanism. Use Caution/Monitor.</p></li><li>ketotifen, ophthalmic<p>ketotifen, ophthalmic, insulin glargine. Other (see comment). Use Caution/Monitor. 
Comment: Combination may result in thrombocytopenia (rare).  Monitor CBC.</p></li><li>levofloxacin<p>levofloxacin increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>linagliptin<p>linagliptin, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>linezolid<p>linezolid increases effects of insulin glargine by unknown mechanism. Use Caution/Monitor.</p></li><li>liraglutide<p>liraglutide, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>lisinopril<p>lisinopril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>lixisenatide<p>lixisenatide, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Risk of hypoglycemia increased when coadministered with basal insulins. Basal insulin dose reduction may be required.</p></li><li>lopinavir<p>lopinavir decreases effects of insulin glargine by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>lurasidone<p>lurasidone, insulin glargine. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>magnesium salicylate<p>magnesium salicylate increases effects of insulin glargine by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required.</p></li><li>marijuana<p>marijuana decreases effects of insulin glargine by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>mecasermin<p>mecasermin increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects.</p></li><li>metformin<p>metformin, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>methyltestosterone<p>methyltestosterone increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. It is important to monitor all patients with type 2 diabetes on antidiabetic agents receiving androgens for changes in glycemic control. Potential for hypoglycemia.</p></li><li>metreleptin<p>insulin glargine, metreleptin.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue.</p></li><li>miglitol<p>miglitol, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>moexipril<p>moexipril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>moxifloxacin<p>moxifloxacin increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>nadolol<p>nadolol, insulin glargine. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance.  Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx.</p></li><li>nateglinide<p>nateglinide, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>nelfinavir<p>nelfinavir decreases effects of insulin glargine by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>norfloxacin<p>norfloxacin increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>ofloxacin<p>ofloxacin increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.</p></li><li>olanzapine<p>olanzapine, insulin glargine. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>opuntia ficus indica<p>opuntia ficus indica increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>paliperidone<p>paliperidone, insulin glargine. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>perindopril<p>perindopril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>phenelzine<p>phenelzine increases effects of insulin glargine by unknown mechanism. Use Caution/Monitor.</p></li><li>pindolol<p>pindolol, insulin glargine. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance.  Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx.</p></li><li>pioglitazone<p>insulin glargine increases toxicity of pioglitazone by unknown mechanism. Use Caution/Monitor. Insulin may increase the fluid retention associated with thiazolidinediones (peroxisome proliferator-activated receptor [PPAR]-gamma agonists).<span><br><br></span>pioglitazone, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>procarbazine<p>procarbazine increases effects of insulin glargine by unknown mechanism. Use Caution/Monitor.</p></li><li>propranolol<p>propranolol, insulin glargine. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance.  Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx.</p></li><li>quetiapine<p>quetiapine, insulin glargine. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>quinapril<p>quinapril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>ramipril<p>ramipril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>rasagiline<p>rasagiline increases effects of insulin glargine by unknown mechanism. Use Caution/Monitor.</p></li><li>risperidone<p>risperidone, insulin glargine. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li><li>ritonavir<p>ritonavir decreases effects of insulin glargine by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>rosiglitazone<p>insulin glargine increases toxicity of rosiglitazone by unknown mechanism. Use Caution/Monitor. Insulin may increase the fluid retention associated with thiazolidinediones (peroxisome proliferator-activated receptor [PPAR]-gamma agonists).<span><br><br></span>rosiglitazone, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>salsalate<p>salsalate increases effects of insulin glargine by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin with high doses of salicylates (3 g/day or more) may increase risk for hypoglycemia. Insulin dose adjustment and increased frequency of glucose monitoring may be required.</p></li><li>saquinavir<p>saquinavir decreases effects of insulin glargine by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>saxagliptin<p>saxagliptin, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>selegiline<p>selegiline increases effects of insulin glargine by unknown mechanism. Use Caution/Monitor.</p></li><li>shark cartilage<p>shark cartilage increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor. Theoretical interaction.</p></li><li>sitagliptin<p>sitagliptin, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate<p>insulin glargine and sodium sulfate/potassium sulfate/magnesium sulfate both decrease  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol<p>insulin glargine and sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol both decrease  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>somatropin<p>somatropin decreases effects of insulin glargine by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>sulfamethoxypyridazine<p>sulfamethoxypyridazine increases effects of insulin glargine by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.</p></li><li>testosterone intranasal<p>testosterone intranasal increases effects of insulin glargine by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of antidiabetic medication.</p></li><li>timolol<p>timolol, insulin glargine. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance.  Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx.</p></li><li>tipranavir<p>tipranavir decreases effects of insulin glargine by Other (see comment). Use Caution/Monitor. 
Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .</p></li><li>tolazamide<p>tolazamide, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>tolbutamide<p>tolbutamide, insulin glargine.
Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.</p></li><li>trandolapril<p>trandolapril increases effects of insulin glargine by pharmacodynamic synergism. Use Caution/Monitor.</p></li><li>tranylcypromine<p>tranylcypromine increases effects of insulin glargine by unknown mechanism. Use Caution/Monitor.</p></li><li>xipamide<p>xipamide decreases levels of insulin glargine by increasing renal clearance. Use Caution/Monitor.</p></li><li>ziprasidone<p>ziprasidone, insulin glargine. Other (see comment). Use Caution/Monitor. 
Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.</p></li>